Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.

Authors:
Address: Faculty of Medicine, Imperial College, South Kensington Campus, London W6 2AZ, UK. lizhang.2009@yahoo.com.cn
Journal:

Publication:

abstract

coxsackievirus B3 (CVB3), along with other enteroviruses, is involved in about 50% of myocarditis cases and in the pathogenesis of dilated cardiomyopathy. Prevention of CVB3 infection is therefore highly desirable. Virus-like particles (VLPs) are structurally similar to native virus particles and therefore are far better immunogens than any other subunit vaccines. Recombinant baculoviruses carrying either the intact, entire coding region of CVB3 or the four individual coding regions for virus proteins 1-4 (VP1-4) were constructed. Expression of CVB3 capsid proteins in insect cells infected with recombinant baculovirus was detected by immunofluorescence and Western blot analysis. Sucrose gradient ultracentrifugation fractions of the infected cell lysates contained peaks of CVB3 antigen with an approximate density of 1.14g/ml. Electron microscopy demonstrated the presence of VLP in these sucrose fractions. The CVB3 VLP was non-infectious in tissue culture. SWR (H-2(q)) mice vaccinated with CVB3 VLP developed antibodies to CVB3 capsid proteins after the first boost. Antibody titre was comparable to the level induced by an attenuated CVB3 vaccine. Vaccinated animals were protected from myocarditis when subsequently challenged with cardiovirulent CVB3 (chimera-2). Vaccination with VLP produced from the complete CVB3 coding region gave a greater immune response and afforded better protection than with VLP from the quadruple expression vector. These results demonstrate that CVB3 capsid proteins expressed in insect cells have the intrinsic capacity to assemble into non-infectious VLP, which afforded protection from CVB3 infection to mice when used as a vaccine.

Related Articles
Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Vaccine. 2011
Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J, Gao Z, Xiong H, Chuai X, Jin Y, Li J, Xian X, Liu G, Xie L, Zhang Y, et al. Vaccine. 2011 Sep 16; 29(40):6894-902. Epub 2011 Jul 29.
Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.
Am J Pathol. 1997
Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.
Zhang H, Morgan-Capner P, Latif N, Pandolfino YA, Fan W, Dunn MJ, Archard LC. Am J Pathol. 1997 Jun; 150(6):2197-207.
Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Infect Immun. 1983
Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Gauntt CJ, Paque RE, Trousdale MD, Gudvangen RJ, Barr DT, Lipotich GJ, Nealon TJ, Duffey PS. Infect Immun. 1983 Feb; 39(2):851-64.
Review Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
Anticancer Res. 2005
Review Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
Tegerstedt K, Franzén AV, Andreasson K, Joneberg J, Heidari S, Ramqvist T, Dalianis T. Anticancer Res. 2005 Jul-Aug; 25(4):2601-8.
Review Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Expert Rev Vaccines. 2008
Review Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Henke A, Jarasch N, Wutzler P. Expert Rev Vaccines. 2008 Dec; 7(10):1557-67.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.